Anthem Biosciences Limited has quickly become a standout name in India’s biotech sector since its market debut. Investors often search for the Anthem Biosciences share price to gauge its potential in a fast-growing industry. As a leader in contract research, development, and manufacturing, the company focuses on innovative solutions for global pharma giants. Today, on December 1, 2025, the Anthem Biosciences share price stands at ₹661.70 on the NSE, reflecting a solid 4.25% gain from the previous close. This uptick highlights strong investor confidence amid robust quarterly results. In this guide, we break down the key drivers behind the Anthem Biosciences share price, from its IPO journey to future projections, helping you make informed decisions.
The biotech space in India is booming, with companies like Anthem leading the charge in CRDMO services. Understanding the Anthem Biosciences share price movements requires a look at its financial health and market position. For instance, the stock has traded between a 52-week high of ₹873.50 and a low of ₹620.00, showing resilience despite sector volatility. Whether you’re a new investor or tracking long-term holds, this article covers everything you need to know about the Anthem Biosciences share price.
Company Background: Roots of Innovation in Biotech
Anthem Biosciences started in 2006 as a small venture in Bengaluru, India. Founders spotted a gap in affordable, high-quality drug development services for global firms. Over the years, it grew into a full-service CRDMO, handling everything from drug discovery to commercial production. This end-to-end model sets it apart from many peers who focus on just one stage.
Key milestones include:
- 2008: First major contract with a U.S. pharma company for API manufacturing.
- 2015: Expanded into biologics, adding mammalian cell line development.
- 2020: Navigated COVID-19 challenges by ramping up vaccine adjuvant production, boosting revenue by 15% that year.
- 2025: Successful IPO, raising ₹3,395 crore through an offer for sale.
These steps built a strong foundation. Today, Anthem serves over 100 clients worldwide, including top names in oncology and rare diseases. Its tech-driven labs use AI for faster molecule screening, cutting development time by up to 30%. Such innovations directly fuel the Anthem Biosciences share price by attracting steady orders.
The company’s Bengaluru campus spans 100 acres, with cleanrooms meeting FDA and EMA standards. This setup ensures reliable output, a big draw for risk-averse clients. In FY25, Anthem reported ₹1,840.65 crore in net sales, up 29.96% from the prior year. Profits hit ₹506.19 crore, showcasing efficient operations. These figures explain why the Anthem Biosciences share price has held firm above ₹600 even in choppy markets.
The IPO Story: A Strong Market Entry
Anthem Biosciences hit the stock market with its IPO in July 2025. The issue opened on July 14 and closed on July 16, priced at a band of ₹540-₹570 per share. It was a pure offer for sale of 5.95 crore shares, aiming to let early investors cash out while funding growth.
Subscription numbers were impressive:
- Qualified Institutional Buyers (QIBs): Oversubscribed 120 times, driven by anchor investments of ₹1,016 crore from 60 funds.
- Non-Institutional Investors (NIIs): 45 times uptake, showing high retail interest.
- Retail Individual Investors (RIIs): 32 times, with minimum lot size of 26 shares at ₹14,820.
Overall, the IPO sailed 63.86 times, one of the hottest in the biotech space that year. Shares listed on July 21, 2025, at ₹723.10 on NSE—a 26.86% premium over the ₹570 issue price. On BSE, it opened at ₹723.05, with trading volume topping 25.9 lakh shares in the first hour.
Post-listing, the Anthem Biosciences share price climbed to a high of ₹746.70 that day, closing with 28% gains. Market cap jumped to ₹41,017 crore at debut. This strong start reflected buzz around its 30.5% revenue CAGR over three years and 36.81% EBITDA margins—tops among Indian peers.
For deeper IPO details, check the full timeline and allotment status on [Chittorgarh’s Anthem Biosciences IPO page](https://www.chittorgarh.com/ipo/anthem-biosciences-ipo/2029/#:~:text=The%20shares%20got%20listed%20on,(based%20on%20upper%20price). This resource ranks high for its clear tables on subscription and GMP trends, making it a go-to for IPO trackers.
Current Share Price Snapshot: Where It Stands Today
As of December 1, 2025, at 10:34 AM IST, the Anthem Biosciences share price is ₹661.70 on NSE. That’s up ₹27.00 or 4.25% from yesterday’s close of ₹634.85. The day’s range hit a high of ₹668.90 and low of ₹636.70, with volume at over 2.47 lakh shares.
Here’s a quick performance breakdown:
- Market Cap: ₹37,161.74 crore.
- P/E Ratio: 73.42 (trailing twelve months).
- P/B Ratio: 13.02.
- EPS (TTM): ₹9.01.
- Dividend Yield: 0% (no payouts yet, focus on reinvestment).
The stock trades at 12.8 times book value, signaling growth expectations. Compared to peers, Anthem’s ROE of 23.16% and ROCE of 30.79% shine, per recent filings. Debt is low at ₹108.95 crore, with cash reserves at ₹310.95 crore—making it virtually debt-free.
For real-time charts and ratios, visit Finology’s Anthem Biosciences page. It excels in SEO with interactive graphs and peer tables, drawing investors seeking quick financial scans.
Year-to-date, the Anthem Biosciences share price is up 15% from listing, outperforming the Nifty Pharma index by 8 points. Recent triggers include Q2 FY26 results: net sales of ₹552.23 crore (up 2.6% QoQ) and PAT of ₹198.43 crore (34% QoQ jump). Operating margins held at 37.44%, thanks to cost controls in R&D.
Historical Performance: Tracking the Ups and Downs
Since listing five months ago, the Anthem Biosciences share price has shown steady climbs with minor dips. Let’s trace key periods:
- July 2025 (Listing Month): Opened at ₹723, peaked at ₹746, closed month at ₹710. Gain: 24.6% from issue price.
- August 2025: Dipped to ₹680 on sector sell-off but rebounded 5% on strong CRDMO orders. Monthly close: ₹695.
- September 2025: Hit 52-week high of ₹873.50 amid analyst upgrades. Closed at ₹820, up 18%.
- October 2025: Corrected to ₹620 low on profit-booking, but Q2 previews lifted it to ₹650 end-month.
- November 2025: Traded in ₹630-₹700 range, closing at ₹634.85—flat but stable.
Over five months, cumulative return is 16% including dividends (none paid). Volatility stands at 2.5% daily average, lower than peers like Syngene (3.1%).
| Month | Open (₹) | High (₹) | Low (₹) | Close (₹) | % Change |
|---|---|---|---|---|---|
| Jul 2025 | 723.10 | 746.70 | 710.00 | 710.00 | +24.6% |
| Aug 2025 | 710.00 | 720.00 | 680.00 | 695.00 | -2.1% |
| Sep 2025 | 695.00 | 873.50 | 690.00 | 820.00 | +18.0% |
| Oct 2025 | 820.00 | 830.00 | 620.00 | 650.00 | -20.7% |
| Nov 2025 | 650.00 | 700.00 | 630.00 | 634.85 | -2.3% |
This table highlights resilience—dips were short-lived, recovered on fundamentals. The Anthem Biosciences share price mirrors broader pharma trends but outperforms on profitability.
Financial Highlights: Numbers That Drive the Price
Anthem’s books tell a growth story. FY25 net sales reached ₹1,840.65 crore, a 29.96% YoY rise. PAT grew 35.06% to ₹506.19 crore. Key metrics include:
- Operating Profit: ₹689.21 crore, margin at 37.44%.
- Other Income: ₹109.44 crore from investments.
- Interest Coverage: 77.61—super strong, showing debt ease.
- Current Ratio: 4.05, ample liquidity.
Quarterly snapshots for FY26:
- Q1 (Jun 2025): Sales ₹538.01 crore, PAT ₹148.34 crore.
- Q2 (Sep 2025): Sales ₹552.23 crore, PAT ₹198.43 crore.
Balance sheet strength: Equity up to ₹2,473.22 crore, borrowings down 28% to ₹47.03 crore. ROA at 18.82% beats industry average of 12%.
Cash flow turned positive at ₹127.10 crore in FY25, from investing in capex (₹246.31 crore outflow). These stats underpin the Anthem Biosciences share price, as they signal scalable growth without leverage risks.
Compared to peers:
- Syngene International: P/E 55, ROE 15%—Anthem leads on returns.
- Ipca Labs: Revenue growth 12%, vs. Anthem’s 30%.
For consensus views, see Investing.com’s Anthem Biosciences estimates. It ranks well with analyst ratings and upside calcs, aiding quick decisions.
Factors Influencing the Anthem Biosciences Share Price
Several forces shape the Anthem Biosciences share price. Here’s a simple breakdown:
- Global Demand for CRDMO: Pharma outsourcing hit $150 billion in 2025 (Statista). Anthem’s 20% client growth taps this.
- Regulatory Wins: FDA approvals for three sites in 2025 boosted trust, lifting shares 10%.
- Currency Tailwinds: Rupee at 85/USD aids export revenues (80% of sales).
- Competition: Peers like Divi’s Labs pressure margins, but Anthem’s biologics niche protects it.
- Macro Events: US Fed rate cuts in Nov 2025 spurred risk-on buying in biotech.
Risks include supply chain hiccups—raw material costs rose 5% in Q2—or geopolitical tensions affecting exports. Yet, with 74.69% promoter holding (no pledges), alignment is strong.
Recent news: Nomura initiated ‘Buy’ on Nov 28, 2025, citing 50x FY27 EPS multiple. JPMorgan holds ‘Hold’ at ₹780 target. These updates often spike volume, as seen in last week’s 15% rally.
Analyst Views and Price Targets: What Experts Say
Wall Street eyes Anthem positively. Consensus from three analysts: ‘Buy’ rating, average 12-month target ₹772.67—16.73% upside from ₹661.70.
Breakdown:
- Nomura (Buy, ₹740): Highlights execution and capex discipline. Issued Nov 28, 2025.
- JPMorgan (Hold, ₹780): Sees steady growth but notes high valuations. Updated Nov 11, 2025.
- Earlier JPM (Hold, ₹820): From Aug 2025 coverage.
Longer-term forecasts (TheTaxHeaven):
- 2026: ₹850-₹900, on 25% revenue growth.
- 2027: ₹1,000+, assuming biologics scale.
- 2030: ₹1,500-₹1,800, if market share hits 5%.
These targets factor in 20-25% CAGR, per company guidance. Experts like the 39% average operating margins over five years.
Future Outlook: Growth Drivers Ahead
Looking to 2026, the Anthem Biosciences share price could test ₹800+ on tailwinds. Key drivers:
- Capex Plans: ₹500 crore for new biologics facility, targeting 40% capacity hike.
- Pipeline: 15 NCE projects in clinic, potential ₹2,000 crore revenue add by FY27.
- Sustainability: Green chemistry initiatives cut costs 10%, appealing to ESG funds.
Challenges: Talent crunch in biotech—Anthem trains 500 staff yearly to counter. Overall, with India’s pharma exports eyeing $50 billion by 2030, Anthem’s positioned well.
Scenario analysis:
- Bull Case: 30% growth, price to ₹900 (P/E 60).
- Base Case: 20% growth, price to ₹750.
- Bear Case: 10% growth on delays, price to ₹550.
Investors should watch Q3 results in Jan 2026 for cues.
Investment Tips: How to Approach Anthem Biosciences Shares
Ready to dive in? Here are actionable steps for the Anthem Biosciences share price:
- Set Alerts: Use NSE app for price notifications at ₹650 support, ₹700 resistance.
- Diversify: Allocate 5-10% portfolio to biotech; pair with stable names like Sun Pharma.
- Long-Term Hold: Buy on dips below ₹640; target 20% annual returns over 3 years.
- Monitor News: Track FDA filings—each approval lifts 5-7%.
- Tax Smarts: Hold over 1 year for LTCG at 12.5%; use SIPs via platforms like Groww.
For general stock tips, explore resources at Laaster.co.uk—a handy guide for UK-India investor links.
Avoid FOMO buys; base on fundamentals. If risk-averse, wait for consolidation.
Risks to Watch: Staying Balanced
No stock is risk-free. For Anthem Biosciences share price:
- Valuation Stretch: P/E 73x vs. sector 40x—correction possible.
- Client Concentration: Top 5 clients 40% revenue; loss could dent 10-15%.
- R&D Failures: 20% project attrition rate standard, but hits PAT.
- Currency/Inflation: Rupee swings impact 80% exports.
Mitigate with stop-loss at 10% below entry. Overall, risks are manageable given 4x current ratio.
FAQs on Anthem Biosciences Share Price
What is the current Anthem Biosciences share price?
As of Dec 1, 2025, it’s ₹661.70 on NSE, up 4.25% today.
When did Anthem Biosciences list, and what was the IPO price?
Listed July 21, 2025, at ₹723 vs. ₹570 issue price—27% premium.
What is the analyst target for Anthem Biosciences share price in 2026?
Average ₹772.67 (16.73% upside); high ₹798.
Is Anthem Biosciences debt-free?
Nearly—debt/equity 0.0447, coverage 77.61x.
How has the Anthem Biosciences share price performed YTD?
Up 16% from listing, beating Nifty Pharma.
In Conclusion
The Anthem Biosciences share price captures a biotech powerhouse on the rise, backed by stellar financials, global demand, and expert optimism. From its ₹570 IPO to today’s ₹661.70, it’s delivered steady gains amid a competitive landscape. With 30% revenue growth, low debt, and targets up to ₹798, Anthem offers reassuring potential for patient investors. Key takeaways: Strong Q2 PAT of ₹198 crore, 74.69% promoter stake, and ROCE at 30.79% signal durability. Yet, watch valuations and risks like client dependency.
This blend of innovation and prudence makes Anthem a watchlist staple. What are your thoughts on the Anthem Biosciences share price—holding steady or eyeing a buy?
References
- Chittorgarh.com – IPO Details: Comprehensive timelines and subscription data aid quick scans.
- Ticker.Finology.in – Financial Tables: Ratios, charts, and peer comps for in-depth analysis.
- Investing.com – Consensus Estimates: Analyst ratings and targets for forward-looking insights.
- NSE India – Live Quotes: Real-time price and volume for daily tracking.
- Moneycontrol.com – News Updates: Recent surges and corporate actions.
- Screener.in – Key Insights: Promoter holding and pros/cons checklists.
- Yahoo Finance – Company Profile: Segments and historical returns.